MABT1551

Anti-Filaggrin Antibody, clone AHF7

• Synonyme(s) : FLG
• Code UNSPSC : 12352203
• Nomenclature NACRES : NA.43

Propriétés

• Source biologique: mouse
• Niveau de qualité: 200
• Forme d'anticorps: purified antibody
• Type de produit anticorps: primary antibodies
• Clone: AHF7, monoclonal
• Poids mol.: observed mol wt ~N/A kDa
• Produit purifié par: ion-exchange chromatography
• Espèces réactives: human
• Conditionnement: antibody small pack of 100
• Technique(s): ELISA: suitable; electron microscopy: suitable; immunofluorescence: suitable; immunohistochemistry: suitable; western blot: suitable
• Isotype: IgG1κ
• Séquence de l'épitope: Unknown
• Numéro d'accès Protein ID: NP_002007
• Numéro d'accès UniProt: P20930
• Température de stockage: -10 to -25°C
• Informations sur le gène: human ... FLG(2312)

Description

Spécificité

Clone AHF7 is a mouse monoclonal antibody that detects the mature form of Filaggrin.

Immunogène

Partially purified Filaggrin from human breast skin tissue.

Application

Quality Control Testing

Evaluated by Immunohistochemistry (Paraffin) in Human skin tissue sections.

Immunohistochemistry (Paraffin) Analysis: A 1:50 dilution of this antibody detected Filaggrin in Human skin tissue sections.

Tested Applications

Immunohistochemistry Applications: A representative lot detected Filaggrin in Immunohistochemistry application. (Simon, M., et al. (1995). Clin Exp Immunol. 100(1):90-8; Simon, M., et al. (1995). J Invest Dermatol. 105(3):432-7; Girbal-Neuhauser, E., et al. (1997). Mol Med. 3(2):145-56; Guy, R., et al. (1998). Dermatology. 196(1):32-7; Guy, R., et al. (1998). J Invest Dermatol. 110(4):410-5; Downie, M.M.T., et al. (2002). Br J Dermatol. 147(5):869-78; Chavanas, S., et al. (2006). J Dermatol Sci. 44(2):63-72).

Immunofluorescence Analysis: A representative lot detected Filaggrin in Immunfluorescence application. (Simon, M., et al. (1995). Clin Exp Immunol. 100(1):90-8; Simon, M., et al. (1995). J Invest Dermatol. 105(3):432-7; Girbal-Neuhauser, E., et al. (1997). Mol Med. 3(2):145-56; Chavanas, S., et al. (2006). J Dermatol Sci. 44(2):63-72).

ELISA Analysis: A representative lot detected Filaggrin in ELISA application. (Simon, M., et al. (1996). Biochem J. 317(Pt1)(Pt1):173-7).

Electron Microscopy: A representative lot detected Filaggrin in Electron Microscopy application. (Simon, M., et al. (1995). J Invest Dermatol. 105(3):432-7).

Western Blotting Analysis: A representative lot detected Filaggrin in Western Blotting application. (Sebbag, M., et al. (1995). J Clin Invest. 95(6):2672-9; Simon, M., et al. (1995). J Invest Dermatol. 105(3):432-7; Simon, M., et al. (1996). Biochem J. 317(Pt1)(Pt1):173-7; Girbal-Neuhauser, E., et al. (1997). Mol Med. 3(2):145-56).

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Description de la cible

Filaggrin (UniProt: P20930; also known as FLG) is encoded by the FLG gene (Gene ID: 2312) in human. Filaggrin, a calcium-binding protein, is synthesized as a large, insoluble, highly phosphorylated precursor with several tandem copies of 324 amino acids in cytoplasmic granules. During terminal differentiation it undergoes dephosphorylation and proteolytic cleavage to remove linker peptides and produce functional basic filaggrin units. It is widely expressed and in skin tissue it is detected mainly in stratum granulosum of the epidermis. During terminal differentiation of mammalian epidermis, it aggregates keratin intermediate filaments and promotes disulfide-bond formation among the intermediate filaments. This creates the intracellular fibrous matrix of the cornified cells. Deimination of arginine to citrulline by peptidylarginine deiminase is reported to result in reduction in its affinity for cytokeratins. The N-terminal region of the mature filaggrin is shown to be heterogenous and is blocked by the formation of pyroglutamate. Clone AHF7 detects only the mature form of filaggrin and does not detect profilaggrin. It exhibits reactivity in various immunochemical applications. (Ref.: Simon, M., et al. (1996). Biochem. J. 317(pt 1); 173 177; Simon, M., et al. (1995). Clin. Exp. Immunol. 100(1); 90-98; Simon, M., et al. (1995). J. Invest. Dermatol. 105(3); 432-437).

Forme physique

Purified mouse monoclonal antibody IgG1 in buffer containing PBS with 0.1% sodium azide with 50% glycerol.

Reconstitution

0.5 mg/mL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Stockage et stabilité

Store at -10°C to -25°C. Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Autres remarques

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Informations sur la sécurité

• Code de la classe de stockage: 12 - Non Combustible Liquids
• Classe de danger pour l'eau (WGK): WGK 2
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable